vs

Side-by-side financial comparison of MAXLINEAR, INC (MXL) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Oncology Institute, Inc. is the larger business by last-quarter revenue ($142.0M vs $137.2M, roughly 1.0× MAXLINEAR, INC). Oncology Institute, Inc. runs the higher net margin — -5.3% vs -32.9%, a 27.6% gap on every dollar of revenue. On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 41.6%). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs 22.1%).

MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

MXL vs TOI — Head-to-Head

Bigger by revenue
TOI
TOI
1.0× larger
TOI
$142.0M
$137.2M
MXL
Growing faster (revenue YoY)
MXL
MXL
+1.4% gap
MXL
43.0%
41.6%
TOI
Higher net margin
TOI
TOI
27.6% more per $
TOI
-5.3%
-32.9%
MXL
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
22.1%
MXL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MXL
MXL
TOI
TOI
Revenue
$137.2M
$142.0M
Net Profit
$-45.1M
$-7.5M
Gross Margin
57.5%
Operating Margin
30.0%
-4.9%
Net Margin
-32.9%
-5.3%
Revenue YoY
43.0%
41.6%
Net Profit YoY
-203.0%
43.0%
EPS (diluted)
$-0.52
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MXL
MXL
TOI
TOI
Q1 26
$137.2M
Q4 25
$136.4M
$142.0M
Q3 25
$126.5M
$136.6M
Q2 25
$108.8M
$119.8M
Q1 25
$95.9M
$104.4M
Q4 24
$92.2M
$100.3M
Q3 24
$81.1M
$99.9M
Q2 24
$92.0M
$98.6M
Net Profit
MXL
MXL
TOI
TOI
Q1 26
$-45.1M
Q4 25
$-14.9M
$-7.5M
Q3 25
$-45.5M
$-16.5M
Q2 25
$-26.6M
$-17.0M
Q1 25
$-49.7M
$-19.6M
Q4 24
$-57.8M
$-13.2M
Q3 24
$-75.8M
$-16.1M
Q2 24
$-39.3M
$-15.5M
Gross Margin
MXL
MXL
TOI
TOI
Q1 26
57.5%
Q4 25
57.6%
Q3 25
56.9%
Q2 25
56.5%
Q1 25
56.1%
Q4 24
55.6%
Q3 24
54.4%
Q2 24
54.6%
Operating Margin
MXL
MXL
TOI
TOI
Q1 26
30.0%
Q4 25
-10.9%
-4.9%
Q3 25
-32.7%
-5.9%
Q2 25
-22.6%
-9.4%
Q1 25
-48.0%
-9.5%
Q4 24
-44.7%
-11.9%
Q3 24
-82.3%
-13.9%
Q2 24
-44.4%
-16.6%
Net Margin
MXL
MXL
TOI
TOI
Q1 26
-32.9%
Q4 25
-10.9%
-5.3%
Q3 25
-36.0%
-12.1%
Q2 25
-24.4%
-14.2%
Q1 25
-51.8%
-18.8%
Q4 24
-62.8%
-13.1%
Q3 24
-93.4%
-16.1%
Q2 24
-42.7%
-15.7%
EPS (diluted)
MXL
MXL
TOI
TOI
Q1 26
$-0.52
Q4 25
$-0.17
$-0.04
Q3 25
$-0.52
$-0.14
Q2 25
$-0.31
$-0.15
Q1 25
$-0.58
$-0.21
Q4 24
$-0.68
$-0.14
Q3 24
$-0.90
$-0.18
Q2 24
$-0.47
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MXL
MXL
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$61.1M
Total DebtLower is stronger
$123.8M
Stockholders' EquityBook value
$454.2M
$-15.7M
Total Assets
$771.3M
$164.7M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MXL
MXL
TOI
TOI
Q1 26
$61.1M
Q4 25
$72.8M
Q3 25
$111.9M
Q2 25
$108.6M
Q1 25
$102.8M
Q4 24
$118.6M
Q3 24
$148.5M
Q2 24
$185.1M
$9.9M
Total Debt
MXL
MXL
TOI
TOI
Q1 26
$123.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
MXL
MXL
TOI
TOI
Q1 26
$454.2M
Q4 25
$451.9M
$-15.7M
Q3 25
$464.7M
$-12.3M
Q2 25
$488.3M
$-9.0M
Q1 25
$493.2M
$5.1M
Q4 24
$516.3M
$3.6M
Q3 24
$556.9M
$15.5M
Q2 24
$617.3M
$29.2M
Total Assets
MXL
MXL
TOI
TOI
Q1 26
$771.3M
Q4 25
$796.4M
$164.7M
Q3 25
$808.1M
$163.6M
Q2 25
$863.7M
$159.8M
Q1 25
$855.3M
$164.0M
Q4 24
$864.6M
$172.7M
Q3 24
$895.3M
$179.2M
Q2 24
$973.2M
$179.6M
Debt / Equity
MXL
MXL
TOI
TOI
Q1 26
0.27×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MXL
MXL
TOI
TOI
Operating Cash FlowLast quarter
$3.2M
Free Cash FlowOCF − Capex
$2.2M
FCF MarginFCF / Revenue
1.5%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MXL
MXL
TOI
TOI
Q1 26
Q4 25
$10.4M
$3.2M
Q3 25
$10.1M
$-12.6M
Q2 25
$10.5M
$-10.2M
Q1 25
$-11.4M
$-5.0M
Q4 24
$-27.8M
$4.2M
Q3 24
$-30.7M
$819.0K
Q2 24
$-2.7M
$-15.7M
Free Cash Flow
MXL
MXL
TOI
TOI
Q1 26
Q4 25
$6.7M
$2.2M
Q3 25
$4.4M
$-13.2M
Q2 25
$9.3M
$-11.4M
Q1 25
$-13.4M
$-5.3M
Q4 24
$-30.0M
$2.4M
Q3 24
$-34.9M
$417.0K
Q2 24
$-5.7M
$-17.5M
FCF Margin
MXL
MXL
TOI
TOI
Q1 26
Q4 25
4.9%
1.5%
Q3 25
3.5%
-9.7%
Q2 25
8.6%
-9.5%
Q1 25
-14.0%
-5.1%
Q4 24
-32.6%
2.4%
Q3 24
-43.0%
0.4%
Q2 24
-6.2%
-17.7%
Capex Intensity
MXL
MXL
TOI
TOI
Q1 26
Q4 25
2.7%
0.7%
Q3 25
4.5%
0.4%
Q2 25
1.1%
1.0%
Q1 25
2.1%
0.3%
Q4 24
2.4%
1.8%
Q3 24
5.1%
0.4%
Q2 24
3.3%
1.9%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MXL
MXL

Segment breakdown not available.

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons